Get the Stockscreener App
3.49
1.13%
-0.04
PDS Biotechnology Corporation stock is currently priced at $3.49, with a 24-hour trading volume of 251.30K.
It has seen a -1.13% decreased in the last 24 hours and a +28.31% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.41 pivot point. If it approaches the $3.67 resistance level, significant changes may occur.
Previous Close:
$3.53
Open:
$3.52
24h Volume:
251.30K
Market Cap:
$128.01M
Revenue:
-
Net Income/Loss:
$-42.94M
P/E Ratio:
-2.1543
EPS:
-1.62
Net Cash Flow:
$-33.64M
1W Performance:
-0.57%
1M Performance:
+28.31%
6M Performance:
-44.52%
1Y Performance:
-50.57%
1D Range:
$3.4101
$3.59
52W Range:
$2.59
$10.27
PDS Biotechnology Corporation Stock (PDSB) Company Profile
Name
PDS Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
300 Connell Drive, Suite 4000, Berkeley Heights
PDS Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
PDS Biotechnology Corporation Stock (PDSB) Latest News
HC Wainwright Weighs in on PDS Biotechnology Co.'s Q2 2024 Earnings (NASDAQ:PDSB) - Defense World
Defense World
HC Wainwright Weighs in on PDS Biotechnology Co.'s Q2 2024 Earnings (NASDAQ:PDSB) - MarketBeat
MarketBeat
PDS Biotechnology (NASDAQ:PDSB) Rating Reiterated by HC Wainwright - Defense World
Defense World
HC Wainwright Comments on PDS Biotechnology Co.'s FY2028 Earnings (NASDAQ:PDSB) - Defense World
Defense World
PDS Biotechnology Corporation (PDSB) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
The InvestChronicle
HC Wainwright Analysts Boost Earnings Estimates for PDS Biotechnology Co. (NASDAQ:PDSB) - MarketBeat
MarketBeat
PDS Biotechnology Corporation Stock (PDSB) Financials Data
PDS Biotechnology Corporation (PDSB) Net Income 2024
PDSB net income (TTM) was -$42.94 million for the quarter ending December 31, 2023, a -5.11% decrease year-over-year.
PDS Biotechnology Corporation (PDSB) Cash Flow 2024
PDSB recorded a free cash flow (TTM) of -$33.64 million for the quarter ending December 31, 2023, a -30.83% decrease year-over-year.
PDS Biotechnology Corporation (PDSB) Earnings per Share 2024
PDSB earnings per share (TTM) was -$1.39 for the quarter ending December 31, 2023, a +4.14% growth year-over-year.
About PDS Biotechnology Corporation
PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. It develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company lead product candidate is PDS0101, an immunotherapeutic for the treatment of cancer. Its synthetic lipid-based immunotherapy platform is Versamune. The company develops Versamune based products for the treatment of cancer. PDS Biotechnology Corporation is based in Berkeley Heights, New Jersey.
0.77%
1.20%
Cap:
|
Volume (24h):